Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Healthy Volunteer
Researchers are investigating new medicines to prevent Human Immunodeficiency Virus Type 1 HIV-1 infection, focusing on women aged 16 to 30 years who are at risk. The study aims to compare the effectiveness and safety of taking MK-8527 once a month against a standard daily pre-exposure prophylaxis PrEP regimen. This phase 3 trial is designed to evaluate if MK-8527 can better prevent HIV-1 infection and how well participants tolerate this medication. Participants will be randomly assigned to one of two groups. One group will take 11 mg of MK-8527 once monthly and a daily placebo matching the standard PrEP medication. The other group will take the daily standard PrEP drugs Emtricitabinetenofovir disoproxil FTCTDF and a monthly placebo matching MK-8527, both for up to approximately two years. After this period, all participants will receive open-label FTCTDF daily for an additional 28 days. During the study, participants will undergo regular monitoring to track new HIV-1 infections, any adverse events, and reasons for discontinuing the study drug due to side effects. The safety and tolerability of MK-8527 will be assessed over the approximately two-year treatment period. The research team will collect data on these outcomes to understand the benefits and risks of MK-8527 as a preventive option for HIV-1 infection.
Actively Recruiting
Researchers are conducting an international observational study to better understand acute infections in adults who are hospitalized. This study focuses on patients with suspected or confirmed acute infectious diseases, including respiratory infections and emerging infectious diseases. The goal is to gather data and biospecimens that will help characterize these infections, identify risk factors, and inform future clinical trial designs. Participants in this study do not receive any experimental treatments as it is purely observational. The study collects detailed clinical data and biological samples from adults admitted to hospitals with acute infections. This includes patients with symptoms starting within the last 30 days. Data from multiple global sites will aid in comprehensively understanding the clinical course and management of these infections. During the study, participants health status will be monitored through various clinical assessments over a 28-day period. Researchers will measure outcomes such as mortality, recovery time, clinical improvement, organ support days, and organ failure scores. The study involves informed consent and follows participants during hospitalization and recovery to gather important information about acute infectious diseases and their progression.